#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13418	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2029	655.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1684	1684	T	728	T	673	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13418	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2029	655.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1418	1418	C	777	C	726	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24248	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3545	681.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1686	1686	A	826	A,G	766,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24248	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3545	681.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2320	2320	C	820	C	764	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24248	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3545	681.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2394	2394	A	778	A	739	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24248	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3545	681.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	2946	2946	C	732	C	685	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1976	folP	855	855	100.0	folP.l15.c4.ctg.1	1405	139.3	1	SNP	p	R229S	1	.	.	685	687	AGC	894	896	AGC	194;191;189	A;G;C	182;179;174	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4994	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3324	149.6	1	SNP	p	S91F	1	.	.	271	273	TTC	540	542	TTC	182;180;180	T;T,C;C	170;171,1;170	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4994	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3324	149.6	1	SNP	p	D95G	1	.	.	283	285	GGC	552	554	GGC	172;173;176	G;G;C	165;164;169	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4994	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3324	149.6	1	SNP	p	G95N	0	.	.	283	285	GGC	552	554	GGC	172;173;176	G;G;C	165;164;169	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	1676	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1370	121.8	1	SNP	p	G45D	0	.	.	133	135	GGC	485	487	GGC	238;240;239	G;G;C	220;221;220	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	812	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1047	77.4	0	.	n	.	0	A197.	DEL	197	197	A	609	609	A	186	A	180	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4602	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3052	150.3	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1571	1573	GTC	167;170;170	G;T;C	152;153;154	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4602	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3052	150.3	1	SNP	p	D86N	0	.	.	256	258	GAC	677	679	GAC	174;172;173	G;A;C	164;159;166	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4602	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3052	150.3	1	SNP	p	R87W	0	.	.	259	261	CGT	680	682	CGT	171;170;171	C,T,A;G;T	161,1,1;161;161	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4602	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3052	150.3	1	SNP	p	R87I	0	.	.	259	261	CGT	680	682	CGT	171;170;171	C,T,A;G;T	161,1,1;161;161	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4602	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3052	150.3	1	SNP	p	S87R	1	.	.	259	261	CGT	680	682	CGT	171;170;171	C,T,A;G;T	161,1,1;161;161	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4602	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3052	150.3	1	SNP	p	S88P	0	.	.	262	264	TCC	683	685	TCC	173;172;173	T;C;C,A	163;163;163,1	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4112	parE	1986	1986	99.95	parE.l15.c30.ctg.1	2368	171.8	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1205	1207	TGC	178;177;174	T;G;C	161;161;159	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4112	parE	1986	1986	99.95	parE.l15.c30.ctg.1	2368	171.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1415	1417	GGC	185;183;183	G;G;C	171;169;168	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	3834	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2336	163.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1219	1221	GCA	201;201;201	G,A;C;A	186,1;188;192	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3834	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2336	163.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1222	1224	ATC	204;201;201	A;T;C	191;189;191	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3834	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2336	163.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1234	1236	GTG	213;208;206	G;T;G,T	195;192;190,1	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3834	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2336	163.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1234	1236	GTG	213;208;206	G;T;G,T	195;192;190,1	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3834	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2336	163.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1738	1740	ACC	191;190;190	A;C;C,G	164;167;169,1	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3834	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2336	163.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1792	1794	GCG	173;170;173	G;C;G	154;140;150	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3834	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2336	163.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1792	1794	GCG	173;170;173	G;C;G	154;140;150	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3834	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2336	163.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1915	1917	GGC	188;184;183	G;G;C	172;169;165	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3834	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2336	163.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1924	1926	GGC	179;177;182	G,A;G;C	164,1;166;169	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	3834	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2336	163.2	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1942	1944	TCG	178;180;182	T,G;C;G	120,10;142;153	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5308	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3103	170.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1650	1652	CCG	194;196;200	C,T;C;G	167,1;173;176	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2126	porA	1146	1146	99.56	porA.l6.c30.ctg.1	1912	110.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	608	608	C	153	C,A	141,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	328	porB1a	984	112	91.96	porB1a.l15.c30.ctg.2	497	31.2	0	.	p	.	0	M18T	NONSYN	52	54	ATG	364	366	ACG	79;79;76	A;C;G	75;74;70	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	328	porB1a	984	112	91.96	porB1a.l15.c30.ctg.2	497	31.2	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	406	408	CAA	38;35;29	C;A;A	32;31;26	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	328	porB1a	984	112	91.96	porB1a.l15.c30.ctg.2	497	31.2	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	412	414	TAC	23;21;20	T;A;C	21;20;19	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2638	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1403	186.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	323	325	GAA	245;245;246	G;A;A	229;230;230	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2638	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1403	186.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	611	613	GAT	220;219;222	G;A;T	206;203;205	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2638	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1403	186.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	734	736	TCA	227;228;232	T;C;A	212;212;218	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2638	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1403	186.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	863	865	GTC	221;222;222	G;T;C	207;208;209	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2638	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1403	186.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1193	1195	GCA	157;155;156	G;C,A;A	146;141,1;147	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2638	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1403	186.0	0	.	p	.	0	D333V	NONSYN	997	999	GAC	1208	1210	GTC	151;149;150	G;T,A;C	142;137,1;141	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2638	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1403	186.0	1	SNP	p	G120K	1	.	.	358	360	AAG	569	571	AAG	238;243;241	A;A;G	225;230;225	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2638	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1403	186.0	1	SNP	p	A121D	1	.	.	361	363	GAC	572	574	GAC	241;241;240	G;A;C	222;218;224	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2638	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1403	186.0	1	SNP	p	D121N	0	.	.	361	363	GAC	572	574	GAC	241;241;240	G;A;C	222;218;224	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	324	porB3	990	116	92.24	porB3.l15.c30.ctg.1	379	30.8	0	.	p	.	0	M18T	NONSYN	52	54	ATG	267	269	ACG	63;63;60	A;C;G	60;59;55	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	324	porB3	990	116	92.24	porB3.l15.c30.ctg.1	379	30.8	0	.	p	.	0	T29A	NONSYN	85	87	ACC	300	302	GCC	58;57;54	G;C;C	50;48;46	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	324	porB3	990	116	92.24	porB3.l15.c30.ctg.1	379	30.8	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	309	311	CAA	35;32;26	C;A;A	29;28;23	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	324	porB3	990	116	92.24	porB3.l15.c30.ctg.1	379	30.8	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	315	317	TAC	20;18;17	T;A;C	18;17;16	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9864	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4943	199.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2032	2034	AAT	213;215;215	A;A;T	202;203;205	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1102	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1014	108.1	1	SNP	p	V57M	1	.	.	169	171	ATG	519	521	ATG	227;230;232	A;T;G	211;212;214	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
